Related Experiment Video
Updated: May 22, 2025
08:53
Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
Published on: July 27, 2022
799
Bakuchiol mitigates colitis through GPR120 activation
Fangfang Xu1, Jixia Wang2, Tianyu Zhang3
1Jiangxi Provincial Key Laboratory for Pharmacodynamic Material Basis of Traditional Chinese Medicine, Ganjiang Chinese Medicine Innovation Center, Nanchang 330000, China.
Summary
Sishen Wan contains bakuchiol, which effectively treats inflammatory bowel disease (IBD) by activating the GPR120 receptor. This study identifies bakuchiol as a promising novel therapeutic agent for IBD.
Area of Science:
- Pharmacology
- Gastroenterology
- Traditional Chinese Medicine
Background:
- Sishen Wan (SSW) is a traditional Chinese herbal formula used for inflammatory bowel disease (IBD).
- The specific active compounds and mechanisms of SSW in treating IBD remain largely unknown.
- This study aimed to elucidate the key components and action mechanisms of SSW.
Purpose of the Study:
- Identify the primary active compound in Sishen Wan (SSW).
- Evaluate the therapeutic efficacy of the identified compound in an inflammatory bowel disease (IBD) model.
- Explore the molecular targets and mechanisms underlying its anti-inflammatory effects.
Main Methods:
- Ultra-high-performance liquid chromatography coupled with mass spectrometry (UHPLC-MS/MS) for chemical analysis.
- Dextran sodium sulfate (DSS)-induced colitis mouse model to assess therapeutic effects.
- Virtual screening, pharmacological assays, RNA sequencing (RNA-seq), and cell-based assays to determine molecular targets and mechanisms.
Main Results:
- Bakuchiol was identified as the main active component of SSW.
- Bakuchiol demonstrated significant therapeutic effects in DSS-induced colitis, comparable or superior to mesalazine.
- Bakuchiol acts as a GPR120 agonist, suppressing inflammatory pathways and partially maintaining epithelial barrier function.
Conclusions:
- Bakuchiol is a key active compound in Sishen Wan (SSW).
- Bakuchiol exerts therapeutic effects in IBD by activating the GPR120 receptor.
- Bakuchiol shows potential as a novel therapeutic agent for inflammatory bowel disease (IBD).
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
115
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
115
01:21Drugs for Treatment of Constipation-Predominant IBS
124
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
124
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
92
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
92
01:17Drugs for Treatment of Diarrhea-Predominant IBS
133
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
133
01:12Role Of Notch Signalling In Intestinal Stem Cell Renewal
2.0K
Notch signaling was first discovered in Drosophila melanogaster, where it is involved in cell lineage differentiation. Notch signaling regulates the maintenance and differentiation of intestinal stem cells or ISCs by controlling the expression of atonal homolog 1 or Atoh1. Atoh1 directs cells to differentiate into secretory cells.
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
2.0K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
126
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
126